Efficacy and Safety of Oral 5-FU Derivatives After Progression of HR <sup>+</sup> /HER2 <sup>−</sup> Metastatic Breast Cancer on CDK4/6 Inhibitor
These findings highlight the potential of oral 5-FU derivatives as effective and safe treatment options to use after progression on CDK4/6i plus ET for patients with HR<sup>+</sup>/HER2<sup>-</sup> MBC.
Authors
- Junji Kawasaki
- Eriko Tokunaga (ORCID: https://orcid.org/0000-0002-1640-5315)
- Yoshiaki Nakamura (ORCID: https://orcid.org/0000-0002-5241-6855)
- Sayuri Akiyoshi
- Yumiko Koi (ORCID: https://orcid.org/0000-0003-0265-9231)
- Wakako Tajiri (ORCID: https://orcid.org/0009-0005-8709-4031)
- Hideki Ijichi (ORCID: https://orcid.org/0000-0001-9378-1915)
- Chinami Koga
Institutions
- National Hospital Organization Kyushu Cancer Center (JP)
Publication Details
- Journal
- Anticancer Research
- Published
- 2025-11-29
- DOI
- https://doi.org/10.21873/anticanres.17895
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 0.00